Press Releases

<<  Back

  View printer-friendly version

Aimmune to Participate in Three Upcoming Investor Conferences

BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 15, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will participate in three upcoming investor conferences in November and December:

Event: Stifel 2019 Healthcare Conference
Date: Wednesday, November 20, 2019
Presentation Time: 3:00 p.m. Eastern Time
Location: New York, NY

Event: Piper Jaffray 31st Annual Healthcare Conference
Date: Tuesday, December 3, 2019
Presentation Time: 9:30 a.m. Eastern Time
Location: New York, NY

Event: Evercore ISI 2nd Annual HealthCONx Conference
Date: Wednesday, December 4, 2019
Presentation Time: 10:35 a.m. Eastern Time
Location: Boston, MA

A live webcast of each fireside chat will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. Replays will be available following each webcast.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing oral treatments for potentially life-threatening food allergies. The Company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first, investigational, complex biologic product candidate, AR101, is being developed as a treatment to reduce the frequency and severity of adverse events following exposure to peanut. The BLA for AR101 is under review by the FDA, which granted AR101 Breakthrough Therapy Designation in 2015 for the desensitization of peanut-allergic patients 4 to 17 years of age. The European Medicines Agency (EMA) is reviewing Aimmune’s Marketing Authorization Application (MAA) for AR101 which Aimmune submitted in June 2019. Aimmune initiated a randomized phase 2 clinical trial of its second investigational, complex biologic product, AR201, for the treatment of egg allergy in August 2019. For more information, please see www.aimmune.com.

Source: Aimmune Therapeutics, Inc.

Investors:
DeDe Sheel
(917) 834-1494
dsheel@aimmune.com

Media:
Jerica Pitts
(312) 858-3469
jpitts@w2ogroup.com